Login Register Cart 0
Generic placeholder image

Current Vascular Pharmacology

Editor-in-Chief

ISSN (Print): 1570-1611
ISSN (Online): 1875-6212

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Antithrombotic Therapy for Peripheral Revascularisation

Author(s): Marco De Carlo*, Marco Angelillis and Riccardo Liga

Volume 18, Issue 3, 2020

Page: [223 - 236] Pages: 14

DOI: 10.2174/1570161117666190206234606

Price: $65

Abstract

Lower extremity artery disease (LEAD) represents a major public health burden, affecting hundreds of millions of people worldwide. Although risk-factor modification, exercise training and medical treatment are the mainstays of the management of LEAD, endovascular or surgical revascularisation is recommended when there is the risk of limb amputation and when drug-resistant claudication severely affects patient lifestyle. Over recent years, the number of peripheral vascular interventions (PVI) has soared worldwide, driven by the improvements in endovascular techniques and devices. This growth was accompanied by a large number of clinical trials aimed at assessing the safety and efficacy of the various revascularisation modalities, while very little evidence was collected regarding the best antithrombotic treatment in patients undergoing peripheral revascularisation. In particular, considering the extensive length of diseased vessels usually treated in PVI, an optimised approach to both platelet function and coagulation cascade is of paramount importance. However, the role of antiplatelet and anticoagulant drugs following lower extremity revascularisation is largely extrapolated from the coronary field. Current guidelines recommend long-term single antiplatelet treatment for the majority of both endovascular and surgical revascularisation procedures, preceded by an initial short-term dual antiplatelet treatment in case of PVI.

We present an overview of the indications and techniques of both endovascular and surgical peripheral revascularisation, followed by an in-depth analysis of the available evidence regarding type and duration of antiplatelet and anticoagulant treatment following revascularisation.

Keywords: Lower extremity artery disease, peripheral vascular interventions, vascular surgery, antiplatelets, anticoagulants, antithrombotic treatment.

« Previous Next »
[1]
Fowkes FG, Rudan D, Rudan I, et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet 2013; 382(9901): 1329-40.
[http://dx.doi.org/10.1016/S0140-6736(13)61249-0] [PMID: 23915883]
[2]
Aboyans V, Braekkan S, Mazzolai L, Sillesen H, Venermo M, De Carlo M. The year 2017 in cardiology: aorta and peripheral circulation. Eur Heart J 2018; 39(9): 730-8.
[http://dx.doi.org/10.1093/eurheartj/ehx800] [PMID: 29300868]
[3]
Sigvant B, Lundin F, Wahlberg E. The risk of disease progression in peripheral arterial disease is higher than expected: a meta-analysis of mortality and disease progression in peripheral arterial disease. Eur J Vasc Endovasc Surg 2016; 51(3): 395-403.
[http://dx.doi.org/10.1016/j.ejvs.2015.10.022] [PMID: 26777541]
[4]
Bhatt DL, Steg PG, Ohman EM, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006; 295(2): 180-9.
[http://dx.doi.org/10.1001/jama.295.2.180] [PMID: 16403930]
[5]
Mukherjee D, Eagle K. The importance of early diagnosis and treatment in peripheral arterial disease: insights from the PARTNERS and REACH registries. Curr Vasc Pharmacol 2010; 8(3): 293-300.
[http://dx.doi.org/10.2174/157016110791112304] [PMID: 19758116]
[6]
Cho I, Chang HJ, Sung JM, et al. Coronary computed tomographic angiography and risk of all-cause mortality and nonfatal myocardial infarction in subjects without chest pain syndrome from the CONFIRM Registry (coronary CT angiography evaluation for clinical outcomes: an international multicenter registry). Circulation 2012; 126(3): 304-13.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.111.081380] [PMID: 22685117]
[7]
Bonaca MP, Scirica BM, Creager MA, et al. Vorapaxar in patients with peripheral artery disease: results from TRA2°P-TIMI 50. Circulation 2013; 127: 1522-9.
[PMID: 23501976]
[8]
Criqui MH, Aboyans V. Epidemiology of peripheral artery disease. Circ Res 2015; 116(9): 1509-26.
[http://dx.doi.org/10.1161/CIRCRESAHA.116.303849] [PMID: 25908725]
[9]
Bonaca MP, Bhatt DL, Storey RF, et al. Ticagrelor for prevention of ischemic events after myocardial infarction in patients with peripheral artery disease. J Am Coll Cardiol 2016; 67(23): 2719-28.
[http://dx.doi.org/10.1016/j.jacc.2016.03.524] [PMID: 27046162]
[10]
Bonaca MP, Nault P, Giugliano RP, et al. Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the Fourier trial (further cardiovascular outcomes research with pcsk9 inhibition in subjects with elevated risk). Circulation 2018; 137(4): 338-50.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.117.032235] [PMID: 29133605]
[11]
Gallino A, Aboyans V, Diehm C, et al. Non-coronary atherosclerosis. Eur Heart J 2014; 35(17): 1112-9.
[http://dx.doi.org/10.1093/eurheartj/ehu071] [PMID: 24595865]
[12]
Hiatt WR, Fowkes FG, Heizer G, et al. Ticagrelor versus clopidogrel in symptomatic peripheral artery disease. N Engl J Med 2017; 376(1): 32-40.
[http://dx.doi.org/10.1056/NEJMoa1611688] [PMID: 27959717]
[13]
Bisdas T, Borowski M, Torsello G. Current practice of first-line treatment strategies in patients with critical limb ischemia. J Vasc Surg 2015; 62(4): 965-73.
[http://dx.doi.org/10.1016/j.jvs.2015.04.441] [PMID: 26187290]
[14]
Sigvant B, Kragsterman B, Falkenberg M, et al. Contemporary cardiovascular risk and secondary preventive drug treatment patterns in peripheral artery disease patients undergoing revascularization. J Vasc Surg 2016; 64(4): 1009-17.
[http://dx.doi.org/10.1016/j.jvs.2016.03.429] [PMID: 27209402]
[15]
Bonaca MP, Gutierrez JA, Creager MA, et al. Acute limb ischemia and outcomes with vorapaxar in patients with peripheral artery disease: results from the trial to assess the effects of vorapaxar in preventing heart attack and stroke in patients with atherosclerosis-thrombolysis in myocardial infarction 50 (TRA2°P-TIMI 50). Circulation 2016; 133(10): 997-1005.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.115.019355] [PMID: 26826179]
[16]
Jones WS, Baumgartner I, Hiatt WR, et al. Ticagrelor compared with clopidogrel in patients with prior lower extremity revascularization for peripheral artery disease. Circulation 2017; 135(3): 241-50.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.116.025880] [PMID: 27840336]
[17]
Aboyans V, Ricco JB, Bartelink MEL, et al. 2017 ESC Guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the european society for vascular surgery (esvs): document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. Eur Heart J 2018; 39(9): 763-816.
[http://dx.doi.org/10.1093/eurheartj/ehx095] [PMID: 28886620]
[18]
Vrsalovic M, Aboyans V. Antithrombotic therapy in lower extremity artery disease. Curr Vasc Pharmacol 2020; 18: 215-22.
[PMID: 30727898]
[19]
Alatri A, Mazzolai L. The bleeding risk in antithrombotic therapies: a narrative review. Curr Vasc Pharmacol 2020; 18: 236-47.
[http://dx.doi.org/10.2174/1570161117666190212112743] [PMID: 30747072]
[20]
Jones WS, Mi X, Qualls LG, et al. Trends in settings for peripheral vascular intervention and the effect of changes in the outpatient prospective payment system. J Am Coll Cardiol 2015; 65(9): 920-7.
[http://dx.doi.org/10.1016/j.jacc.2014.12.048] [PMID: 25744009]
[21]
Armstrong EJ, Bishu K, Waldo SW. Endovascular treatment of infrapopliteal peripheral artery disease. Curr Cardiol Rep 2016; 18(4): 34.
[http://dx.doi.org/10.1007/s11886-016-0708-y] [PMID: 26915012]
[22]
Rocha-Singh KJ, Beckman JA, Ansel G, et al. Patient-level meta-analysis of 999 claudicants undergoing primary femoropopliteal nitinol stent implantation. Catheter Cardiovasc Interv 2017; 89(7): 1250-6.
[http://dx.doi.org/10.1002/ccd.27029] [PMID: 28303688]
[23]
Tepe G, Zeller T, Albrecht T, et al. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Engl J Med 2008; 358(7): 689-99.
[http://dx.doi.org/10.1056/NEJMoa0706356] [PMID: 18272892]
[24]
Dake MD, Ansel GM, Jaff MR, et al. Paclitaxel-eluting stents show superiority to balloon angioplasty and bare metal stents in femoropopliteal disease: twelve-month Zilver PTX randomized study results. Circ Cardiovasc Interv 2011; 4(5): 495-504.
[http://dx.doi.org/10.1161/CIRCINTERVENTIONS.111.962324] [PMID: 21953370]
[25]
Werk M, Albrecht T, Meyer DR, et al. Paclitaxel-coated balloons reduce restenosis after femoro-popliteal angioplasty: evidence from the randomized PACIFIER trial. Circ Cardiovasc Interv 2012; 5(6): 831-40.
[http://dx.doi.org/10.1161/CIRCINTERVENTIONS.112.971630] [PMID: 23192918]
[26]
Scheinert D, Duda S, Zeller T, et al. The LEVANT I (Lutonix paclitaxel-coated balloon for the prevention of femoropopliteal restenosis) trial for femoropopliteal revascularization: first-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty. JACC Cardiovasc Interv 2014; 7(1): 10-9.
[http://dx.doi.org/10.1016/j.jcin.2013.05.022] [PMID: 24456716]
[27]
Rosenfield K, Jaff MR, White CJ, et al. Trial of a paclitaxel-coated balloon for femoropopliteal artery disease. N Engl J Med 2015; 373(2): 145-53.
[http://dx.doi.org/10.1056/NEJMoa1406235] [PMID: 26106946]
[28]
Tepe G, Laird J, Schneider P, et al. Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease: 12-month results from the IN.PACT SFA randomized trial. Circulation 2015; 131(5): 495-502.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.114.011004] [PMID: 25472980]
[29]
Schroeder H, Werner M, Meyer DR, et al. Low-dose paclitaxel-coated versus uncoated percutaneous transluminal balloon angioplasty for femoropopliteal peripheral artery disease: one-year results of the ILLUMENATE European randomized clinical trial (randomized trial of a novel paclitaxel-coated percutaneous angioplasty balloon). Circulation 2017; 135(23): 2227-36.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.116.026493] [PMID: 28424223]
[30]
Steiner S, Willfort-Ehringer A, Sievert H, et al. 12-month results from the first-in-human randomized study of the ranger paclitaxel-coated balloon for femoropopliteal treatment. JACC Cardiovasc Interv 2018; 11(10): 934-41.
[http://dx.doi.org/10.1016/j.jcin.2018.01.276] [PMID: 29730375]
[31]
Gray WA, Keirse K, Soga Y, et al. A polymer-coated, paclitaxel-eluting stent (Eluvia) versus a polymer-free, paclitaxel-coated stent (Zilver PTX) for endovascular femoropopliteal intervention (IMPERIAL): a randomised, non-inferiority trial. Lancet 2018; 392(10157): 1541-51.
[http://dx.doi.org/10.1016/S0140-6736(18)32262-1] [PMID: 30262332]
[32]
Cassese S, Ndrepepa G, Liistro F, et al. Drug-coated balloons for revascularization of infrapopliteal arteries: a meta-analysis of randomized trials. JACC Cardiovasc Interv 2016; 9(10): 1072-80.
[http://dx.doi.org/10.1016/j.jcin.2016.02.011] [PMID: 27131439]
[33]
Katsanos K, Kitrou P, Spiliopoulos S, Diamantopoulos A, Karnabatidis D. Comparative effectiveness of plain balloon angioplasty, bare metal stents, drug-coated balloons, and drug-eluting stents for the treatment of infrapopliteal artery disease: systematic review and bayesian network meta-analysis of randomized controlled trials. J Endovasc Ther 2016; 23(6): 851-63.
[http://dx.doi.org/10.1177/1526602816671740] [PMID: 27708143]
[34]
Jaff MR, Nelson T, Ferko N, Martinson M, Anderson LH, Hollmann S. endovascular interventions for femoropopliteal peripheral artery disease: a network meta-analysis of current technologies. J Vasc Interv Radiol 2017; 28(12): 1617-27.
[http://dx.doi.org/10.1016/j.jvir.2017.08.003] [PMID: 29031986]
[35]
Thieme M, Von Bilderling P, Paetzel C, Karnabatidis D, Perez Delgado J, Lichtenberg M. The 24-month results of the lutonix global sfa registry: worldwide experience with lutonix drug-coated balloon. JACC Cardiovasc Interv 2017; 10(16): 1682-90.
[http://dx.doi.org/10.1016/j.jcin.2017.04.041] [PMID: 28780030]
[36]
Micari A, Nerla R, Vadalà G, et al. 2-year results of paclitaxel-coated balloons for long femoropopliteal artery disease: evidence from the SFA-long study. JACC Cardiovasc Interv 2017; 10(7): 728-34.
[http://dx.doi.org/10.1016/j.jcin.2017.01.028] [PMID: 28385412]
[37]
Micari A, Brodmann M, Keirse K, et al. Drug-coated balloon treatment of femoropopliteal lesions for patients with intermittent claudication and ischemic rest pain: 2-year results from the IN.PACT global study. JACC Cardiovasc Interv 2018; 11(10): 945-53.
[http://dx.doi.org/10.1016/j.jcin.2018.02.019] [PMID: 29798770]
[38]
Schroë H, Holden AH, Goueffic Y, et al. Stellarex drug-coated balloon for treatment of femoropopliteal arterial disease-The ILLUMENATE Global Study: 12-Month results from a prospective, multicenter, single-arm study. Catheter Cardiovasc Interv 2018; 91(3): 497-504.
[http://dx.doi.org/10.1002/ccd.27348] [PMID: 29086462]
[39]
Ott I, Cassese S, Groha P, et al. randomized comparison of paclitaxel-eluting balloon and stenting versus plain balloon plus stenting versus directional atherectomy for femoral artery disease (ISAR-STATH). Circulation 2017; 135(23): 2218-26.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.116.025329] [PMID: 28424222]
[40]
Zeller T, Langhoff R, Rocha-Singh KJ, et al. Directional atherectomy followed by a paclitaxel-coated balloon to inhibit restenosis and maintain vessel patency: twelve-month results of the DEFINITIVE AR study. Circ Cardiovasc Interv 2017; 10(9): 10.
[http://dx.doi.org/10.1161/CIRCINTERVENTIONS.116.004848] [PMID: 28916599]
[41]
Habib A, Petrucci G, Rocca B. Pathophysiology of Thrombosis in Peripheral Artery Disease. Curr Vasc Pharmacol 2020; 18: 204-14.
[PMID: 30727897]
[42]
Capell WH, Bonaca MP, Nehler MR, et al. Rationale and design for the Vascular Outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral artery disease (VOYAGER PAD). Am Heart J 2018; 199: 83-91.
[http://dx.doi.org/10.1016/j.ahj.2018.01.011] [PMID: 29754671]
[43]
Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery (The Dutch Bypass Oral Anticoagulants or Aspirin Study): a randomised trial. Lancet 2000; 355(9201): 346-51.
[http://dx.doi.org/10.1016/S0140-6736(99)07199-8] [PMID: 10665553]
[44]
Johnson WC, Williford WO. Benefits, morbidity, and mortality associated with long-term administration of oral anticoagulant therapy to patients with peripheral arterial bypass procedures: a prospective randomized study. J Vasc Surg 2002; 35(3): 413-21.
[http://dx.doi.org/10.1067/mva.2002.121847] [PMID: 11877686]
[45]
Jivegård L, Drott C, Gelin J, et al. Effects of three months of low molecular weight heparin (dalteparin) treatment after bypass surgery for lower limb ischemia--a randomised placebo-controlled double blind multicentre trial. Eur J Vasc Endovasc Surg 2005; 29(2): 190-8.
[http://dx.doi.org/10.1016/j.ejvs.2004.11.011] [PMID: 15649728]
[46]
Iida O, Nanto S, Uematsu M, Morozumi T, Kitakaze M, Nagata S. Cilostazol reduces restenosis after endovascular therapy in patients with femoropopliteal lesions. J Vasc Surg 2008; 48(1): 144-9.
[http://dx.doi.org/10.1016/j.jvs.2008.02.062] [PMID: 18482817]
[47]
Belch JJ, Dormandy J, Biasi GM, et al. Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial. J Vasc Surg 2010; 52: 825-33.
[PMID: 20678878]
[48]
Burdess A, Nimmo AF, Garden OJ, et al. Randomized controlled trial of dual antiplatelet therapy in patients undergoing surgery for critical limb ischemia. Ann Surg 2010; 252(1): 37-42.
[http://dx.doi.org/10.1097/SLA.0b013e3181e40dde] [PMID: 20562608]
[49]
Tepe G, Bantleon R, Brechtel K, et al. Management of peripheral arterial interventions with mono or dual antiplatelet therapy--the MIRROR study: a randomised and double-blinded clinical trial. Eur Radiol 2012; 22(9): 1998-2006.
[http://dx.doi.org/10.1007/s00330-012-2441-2] [PMID: 22569995]
[50]
Monaco M, Di Tommaso L, Pinna GB, Lillo S, Schiavone V, Stassano P. Combination therapy with warfarin plus clopidogrel improves outcomes in femoropopliteal bypass surgery patients. J Vasc Surg 2012; 56(1): 96-105.
[http://dx.doi.org/10.1016/j.jvs.2012.01.004] [PMID: 22551909]
[51]
Soga Y, Hamasaki T, Edahiro R, et al. sustained effectiveness of cilostazol after endovascular treatment of femoropopliteal lesions: midterm follow-up from the sufficient treatment of peripheral intervention by cilostazol (STOP-IC) study. J Endovasc Ther 2018; 25(3): 306-12.
[http://dx.doi.org/10.1177/1526602818771358] [PMID: 29706129]
[52]
Anand SS, Bosch J, Eikelboom JW, et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet 2018; 391(10117): 219-29.
[http://dx.doi.org/10.1016/S0140-6736(17)32409-1] [PMID: 29132880]
[53]
Heiss HW, Just H, Middleton D, Deichsel G. Reocclusion prophylaxis with dipyridamole combined with acetylsalicylic acid following PTA. Angiology 1990; 41(4): 263-9.
[http://dx.doi.org/10.1177/000331979004100402] [PMID: 2140251]
[54]
Study group on pharmacological treatment after PTA. Platelet inhibition with ASA/dipyridamole after percutaneous balloon angioplasty in patients with symptomatic lower limb arterial disease. A prospective double-blind trial. Eur J Vasc Surg 1994; 8: 83-8.
[http://dx.doi.org/10.1016/S0950-821X(05)80126-4] [PMID: 8307222]
[55]
Robertson L, Ghouri MA, Kovacs F. Antiplatelet and anticoagulant drugs for prevention of restenosis/reocclusion following peripheral endovascular treatment. Cochrane Database Syst Rev 2012; 8(8) CD002071
[http://dx.doi.org/10.1002/14651858.CD002071.pub3] [PMID: 22895926]
[56]
Strobl FF, Brechtel K, Schmehl J, et al. Twelve-month results of a randomized trial comparing mono with dual antiplatelet therapy in endovascularly treated patients with peripheral artery disease. J Endovasc Ther 2013; 20(5): 699-706.
[http://dx.doi.org/10.1583/13-4275MR.1] [PMID: 24093324]
[57]
Peeters Weem SM, van Haelst ST, den Ruijter HM, Moll FL, de Borst GJ. Lack of evidence for dual antiplatelet therapy after endovascular arterial procedures: a meta-analysis. Eur J Vasc Endovasc Surg 2016; 52(2): 253-62.
[http://dx.doi.org/10.1016/j.ejvs.2016.04.023] [PMID: 27241270]
[58]
Soden PA, Zettervall SL, Ultee KH, et al. Dual antiplatelet therapy is associated with prolonged survival after lower extremity revascularization. J Vasc Surg 2016; 64(6): 1633-44.
[http://dx.doi.org/10.1016/j.jvs.2016.05.098] [PMID: 27575814]
[59]
Clinicaltrials.gov. Effects of prolonged DAPT after lower extremity percutane-ous transluminal angioplasty in patients with LE-PAD 2016. Available from:. https://clinicaltrials.gov/ct2/show/NCT02798913 [cited 2018 December 1]
[60]
Clinicaltrials.gov. Antiplatelet strategy for peripheral arterial interventions for revascularization of lower extremities (ASPIRE) 2014. [cited 2018 December 1]. Available from. https://clinicaltrials.gov/ ct2/show/NCT02217501
[61]
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348(9038): 1329-39.
[http://dx.doi.org/10.1016/S0140-6736(96)09457-3] [PMID: 8918275]
[62]
Koppensteiner R, Spring S, Amann-Vesti BR, et al. Low-molecular-weight heparin for prevention of restenosis after femoropopliteal percutaneous transluminal angioplasty: a randomized controlled trial. J Vasc Surg 2006; 44(6): 1247-53.
[http://dx.doi.org/10.1016/j.jvs.2006.07.044] [PMID: 17145426]
[63]
Ullery BW, Tran K, Itoga N, Casey K, Dalman RL, Lee JT. Safety and efficacy of antiplatelet/anticoagulation regimens after Viabahn stent graft treatment for femoropopliteal occlusive disease. J Vasc Surg 2015; 61(6): 1479-88.
[http://dx.doi.org/10.1016/j.jvs.2014.12.062] [PMID: 25704407]
[64]
Gibson CM, Mehran R, Bode C, et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med 2016; 375(25): 2423-34.
[http://dx.doi.org/10.1056/NEJMoa1611594] [PMID: 27959713]
[65]
Cannon CP, Bhatt DL, Oldgren J, et al. Dual antithrombotic therapy with dabigatran after pci in atrial fibrillation. N Engl J Med 2017; 377(16): 1513-24.
[http://dx.doi.org/10.1056/NEJMoa1708454] [PMID: 28844193]
[66]
Wallentin L, Yusuf S, Ezekowitz MD, et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 2010; 376(9745): 975-83.
[http://dx.doi.org/10.1016/S0140-6736(10)61194-4] [PMID: 20801496]
[67]
Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365(11): 981-92.
[http://dx.doi.org/10.1056/NEJMoa1107039] [PMID: 21870978]
[68]
Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365(10): 883-91.
[http://dx.doi.org/10.1056/NEJMoa1009638] [PMID: 21830957]
[69]
Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369(22): 2093-104.
[http://dx.doi.org/10.1056/NEJMoa1310907] [PMID: 24251359]
[70]
Jones WS, Hellkamp AS, Halperin J, et al. Efficacy and safety of rivaroxaban compared with warfarin in patients with peripheral artery disease and non-valvular atrial fibrillation: insights from ROCKET AF. Eur Heart J 2014; 35(4): 242-9.
[http://dx.doi.org/10.1093/eurheartj/eht492] [PMID: 24302273]
[71]
Hu PT, Lopes RD, Stevens SR, et al. Efficacy and Safety of apixaban compared with warfarin in patients with atrial fibrillation and peripheral artery disease: insights from the ARISTOTLE trial. J Am Heart Assoc 2017; 6(1) e004699
[http://dx.doi.org/10.1161/JAHA.116.004699] [PMID: 28096100]
[72]
Moll F, Baumgartner I, Jaff M, et al. edoxaban plus aspirin vs dual antiplatelet therapy in endovascular treatment of patients with peripheral artery disease: results of the ePAD trial. J Endovasc Ther 2018; 25(2): 158-68.
[http://dx.doi.org/10.1177/1526602818760488] [PMID: 29552984]
[73]
Clinicaltrials.gov. Efficacy and safety of rivaroxaban in reducing the risk of major thrombotic vascular events in subjects with symptomatic peripheral artery disease undergoing peripheral revascularization procedures of the lower extremities (VOYAGER PAD) 2015. Available from. https://clinicaltrials.gov/ct2/show/NCT02504216
[74]
Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy--II: Maintenance of vascular graft or arterial patency by antiplatelet therapy. BMJ 1994; 308(6922): 159-68.
[http://dx.doi.org/10.1136/bmj.308.6922.159] [PMID: 8312766]
[75]
Bedenis R, Lethaby A, Maxwell H, Acosta S, Prins MH. Antiplatelet agents for preventing thrombosis after peripheral arterial bypass surgery. Cochrane Database Syst Rev 2015; 19(2) CD000535
[http://dx.doi.org/10.1002/14651858.CD000535.pub3] [PMID: 25695213]
[76]
Becquemin JP. Effect of ticlopidine on the long-term patency of saphenous-vein bypass grafts in the legs. N Engl J Med 1997; 337(24): 1726-31.
[http://dx.doi.org/10.1056/NEJM199712113372404] [PMID: 9392698]
[77]
Liang NL, Baril DT, Avgerinos ED, Leers SA, Makaroun MS, Chaer RA. Comparative effectiveness of anticoagulation on midterm infrainguinal bypass graft patency. J Vasc Surg 2017; 66(2): 499-505.
[http://dx.doi.org/10.1016/j.jvs.2016.12.141] [PMID: 28400219]
[78]
Laird JR, Katzen BT, Scheinert D, et al. Nitinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal popliteal artery: twelve-month results from the RESILIENT randomized trial. Circ Cardiovasc Interv 2010; 3(3): 267-76.
[http://dx.doi.org/10.1161/CIRCINTERVENTIONS.109.903468] [PMID: 20484101]
[79]
Krankenberg H, Schlüter M, Steinkamp HJ, et al. Nitinol stent implantation versus percutaneous transluminal angioplasty in superficial femoral artery lesions up to 10 cm in length: the femoral artery stenting trial (FAST). Circulation 2007; 116(3): 285-92.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.107.689141] [PMID: 17592075]
[80]
Zeller T, Baumgartner I, Scheinert D, et al. Drug-eluting balloon versus standard balloon angioplasty for infrapopliteal arterial revascularization in critical limb ischemia: 12-month results from the IN.PACT DEEP randomized trial. J Am Coll Cardiol 2014; 64(15): 1568-76.
[http://dx.doi.org/10.1016/j.jacc.2014.06.1198] [PMID: 25301459]
[81]
Schulte KL, Pilger E, Schellong S, et al. Primary self-expanding nitinol stenting vs balloon angioplasty with optional bailout stenting for the treatment of infrapopliteal artery disease in patients with severe intermittent claudication or critical limb ischemia (EXPAND study). J Endovasc Ther 2015; 22(5): 690-7.
[http://dx.doi.org/10.1177/1526602815598955] [PMID: 26245919]
[82]
Brodmann M, Froehlich H, Dorr A, et al. Percutaneous transluminal angioplasty versus primary stenting in infrapopliteal arteries in critical limb ischemia. Vasa 2011; 40(6): 482-90.
[http://dx.doi.org/10.1024/0301-1526/a000152] [PMID: 22090182]
[83]
Randon C, Jacobs B, De Ryck F, Vermassen F. Angioplasty or primary stenting for infrapopliteal lesions: results of a prospective randomized trial. Cardiovasc Intervent Radiol 2010; 33(2): 260-9.
[http://dx.doi.org/10.1007/s00270-009-9765-6] [PMID: 19957178]
[84]
Scheinert D, Katsanos K, Zeller T, et al. A prospective randomized multicenter comparison of balloon angioplasty and infrapopliteal stenting with the sirolimus-eluting stent in patients with ischemic peripheral arterial disease: 1-year results from the ACHILLES trial. J Am Coll Cardiol 2012; 60(22): 2290-5.
[http://dx.doi.org/10.1016/j.jacc.2012.08.989] [PMID: 23194941]
[85]
Rastan A, Krankenberg H, Baumgartner I, et al. Stent placement versus balloon angioplasty for the treatment of obstructive lesions of the popliteal artery: a prospective, multicenter, randomized trial. Circulation 2013; 127(25): 2535-41.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.113.001849] [PMID: 23694965]
[86]
Lammer J, Zeller T, Hausegger KA, et al. Heparin-bonded covered stents versus bare-metal stents for complex femoropopliteal artery lesions: the randomized VIASTAR trial (Viabahn endoprosthesis with PROPATEN bioactive surface [VIA] versus bare nitinol stent in the treatment of long lesions in superficial femoral artery occlusive disease). J Am Coll Cardiol 2013; 62(15): 1320-7.
[http://dx.doi.org/10.1016/j.jacc.2013.05.079] [PMID: 23831445]
[87]
Krankenberg H, Zeller T, Ingwersen M, et al. Self-expanding versus balloon-expandable stents for iliac artery occlusive disease: the randomized ICE trial. JACC Cardiovasc Interv 2017; 10(16): 1694-704.
[http://dx.doi.org/10.1016/j.jcin.2017.05.015] [PMID: 28838480]
[88]
Mwipatayi BP, Thomas S, Wong J, et al. A comparison of covered vs bare expandable stents for the treatment of aortoiliac occlusive disease. J Vasc Surg 2011; 54(6): 1561-70.
[http://dx.doi.org/10.1016/j.jvs.2011.06.097] [PMID: 21906903]
[89]
Goode SD, Cleveland TJ, Gaines PA. Randomized clinical trial of stents versus angioplasty for the treatment of iliac artery occlusions (STAG trial). Br J Surg 2013; 100(9): 1148-53.
[http://dx.doi.org/10.1002/bjs.9197] [PMID: 23842828]
[90]
Schillinger M, Sabeti S, Loewe C, et al. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Engl J Med 2006; 354(18): 1879-88.
[http://dx.doi.org/10.1056/NEJMoa051303] [PMID: 16672699]

Rights & Permissions Print Cite
Article Metrics
19
3
© 2024 Bentham Science Publishers | Privacy Policy